DYT1, an autosomal dominant form of dystonia, almost universally caused by an in-frame GAG deletion in the *TOR1A* gene^[@R1]^ with reduced clinical penetrance, reported at about 33%.^[@R2],[@R3]^ In addition to the GAG deletion, a few private sequence variants in *TOR1A* have been linked to the appearance of dystonia,^[@R4],[@R5]^ and biallelic mutations in this gene were recently identified in patients with a severe congenital syndrome.^[@R6]^ Recent studies have estimated the prevalence of dystonia in different populations.^[@R7],[@R8]^ However, most focus on adult-onset isolated dystonia. With the advent of precision medicine, it is important to ascertain the prevalence of genetically defined forms. This epidemiologic information is important not only to extrapolate the burden of the disease but also to inform those with potential interest on therapeutic development about the target population.

Here, we designed a genetic ascertainment study that quantifies the prevalence of the GAG deletion and other rare pathogenic variants in *TOR1A* in the general population and interrogated the electronic health records of *TOR1A* variant carriers to estimate the prevalence of DYT1 dystonia.

Methods {#s1}
=======

We analyzed exome sequencing data from the Genome Aggregation Database (gnomAD) and Penn Medicine Biobank (PMBB). gnomAD is a coalition of investigators that have generated harmonized exome sequencing data freely available to the scientific community (from 125,748 unrelated individuals of various population genetic studies).^[@R9]^ The PMBB, approved by the University of Pennsylvania Institutional Review Board, consists of over 60,000 patients from clinical practice sites of the University of Pennsylvania Health System who have given appropriate consent regarding access to all available electronic health records (EHRs). Participants are recruited independent of diagnosis and at multiple locations, from clinical visits to those undergoing blood draws or radiologic studies for any reason, among others. This study included a subset of 11,451 individuals who have undergone whole-exome sequencing, for which we obtained whole-exome sequences as generated via DNA extracted from stored buffy coats by the Regeneron Genetics Center (Tarrytown, NY) and mapped these sequences to GRCh37 as previously described.^[@R10]^ Furthermore, *International Classification of Diseases* (*ICD*) *Ninth Revision* and *Tenth Revision* (*ICD-10*) disease diagnosis codes and procedural billing codes were extracted from the patients\' EHR.

We first evaluated the frequency of the sequence variant responsible for almost all cases of DYT1 dystonia (exon5:c.907_909del:p.303_303del).^[@R1]^ Next, we queried the PMBB data set for other reported private pathogenic variants^[@R4],[@R5]^ and to identify other novel predicted deleterious missense variants in *TOR1A*, evaluating their frequency in gnomAD. For prediction of deleterious missense variants, we used the Rare Exonic Variant Ensemble Learner (REVEL)^[@R11]^ selecting the top 20% REVEL scores to be considered deleterious. For all participants from the PMBB harboring known pathogenic or predicted deleterious variants, their EHR was reviewed for the presence of a diagnosis of dystonia, description of a phenotype suspected to be dystonia, or a family history of dystonia or similar neurologic syndrome.

Finally, we evaluated the PMBB data set for the frequency of the exon4:c.G646C:p.D216H single nucleotide polymorphism (SNP), known to influence the penetrance of the common DYT1 mutation^[@R3]^ but also proposed to be a risk factor for isolated dystonia independent of the GAG deletion.^[@R12]^ We identified carriers of the minor allele in heterozygous and homozygous state. As manual evaluation of the 11,451 medical charts is not feasible, we queried the diagnostic codes from the EMR of all PMBB participants with exome data for *ICD-9* codes 333.6, 333.7, and 333.8 to correlate the p.D216H polymorphism with dystonia.

Data availability {#s1-1}
-----------------

Anonymized data not published within the article will be shared by request from any qualified investigator.

Results {#s2}
=======

We used the minor allele frequencies reported for the GAG deletion in gnomAD, all in a heterozygous state, to calculate the carrier frequency ([table 1](#T1){ref-type="table"}). To confirm this prevalence in an independent US-based data set, we evaluated carrier frequency in the PMBB. Overall, the data were consistent between both data sets, with a frequency in the entire data set of 20 carriers per 100,000. Although there is no clinical information available for gnomAD participants, we reviewed the EHR for the 3 participants carrying the GAG deletion in the PMBB (54- and 85-year-old men and 88-year-old woman). None had any evidence of a neurologic disorder affecting motor function, with no mention of neurologic disease or disability in their family history (which was recorded). However, they had not been evaluated by a movement disorders neurologist.

###### 

Prevalence of GAG deletion in the 2 data sets and in aggregate
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Next, we aimed to estimate the prevalence of this variant in the United States based on these data ([table 2](#T2){ref-type="table"}). However, this cannot be simply extrapolated from the full gnomAD data set. The GAG deletion is overrepresented in Ashkenazi Jewish (AJ),^[@R2]^ a subgroup that represents 4% of gnomAD participants but only 2% of the US population.^[@R13]^ This subgroup had a carrier frequency of 0.003. For that reason, we also estimated the expected prevalence of the GAG deletion based on both the PMBB data set (US based) and in gnomAD including an AJ subgroup adjusted to represent only 2% of the sample. As shown in [table 2](#T2){ref-type="table"}, this yields a range of prevalence of the GAG deletion in the United States of 17.6--26.2 carriers/100,000. [Table 2](#T2){ref-type="table"} also shows the number of predicted carriers and symptomatic DYT1 patients, assuming a 33.3% penetrance. We did not collect information to identify an AJ subgroup in the PMBB data set, but 75% of that sample is of European descent.

###### 

Estimated prevalence of carrier status and clinically manifest DYT1 dystonia in the United States
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We also queried the PMBB data set for other previously reported likely pathogenic variants in *TOR1A*^[@R4],[@R5],[@R14]^ and identified 3 participants, with 5 additional participants with predicted deleterious variants ([table 3](#T3){ref-type="table"}). EHR review disclosed that none of them had dystonia or any other motor or neurologic disorder. Similarly, there was no mention of family history of dystonia or other neurologic disorder in their records. None of the patients had been evaluated by a neurologist in our institution.

###### 

Prevalence of previously reported pathogenic variants and new predicted deleterious variants in *TOR1A* in PMBB, with carrier frequencies in gnomAD
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Finally, we evaluated for the frequency of the D216H polymorphism among the PMBB exome data set. In addition to influencing DYT1 penetrance, it has been proposed as a risk factor for isolated dystonia.^[@R12]^ The frequency of the SNP encoding for aspartic acid (88.3%) and histidine (11.7%) was as previously described,^[@R3]^ with the number of participants per genotype and frequency of diagnostic codes for dystonia in their EHR shown in [table 4](#T4){ref-type="table"}.

###### 

Distribution of the clinically significant SNP (encoding for either an aspartic acid or histidine in amino acid 216) in the PMBB data set, correlated with the presence of diagnostic codes for dystonia in the EMR
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Discussion {#s3}
==========

In this work, we estimate the frequency of the most common DYT1-causing mutation in the general population using exome data sets representing over 135,000 individuals, making it a robust genetic ascertainment study. The only previous attempt to quantify the prevalence of the GAG deletion in the general population was genotyping of the GAG deletion in samples from a neonatal screen in South-Eastern France, identifying 1 mutation among 12,000 births.^[@R15]^ Our study includes 2 additional independent data sets. All yielded consistent findings. These data have very important implications for therapeutic development in DYT1, allowing to quantitatively estimate the target population. In addition, we evaluated the frequency of other rare potentially pathogenic and predicted deleterious variants in *TOR1A*, linking it to clinical information in PMBB participants. This additional piece of information was not used for our prevalence estimates, as the pathogenicity of some of these variants is still debated. However, it will help clarify their role in dystonia as their frequency and clinical correlates are evaluated in additional data sets.

Dystonia is clinically and etiologically very heterogeneous,^[@R16]^ and DYT1 represents a very small fraction of patients with dystonia. A well-designed study recently estimated the prevalence of adult-onset isolated idiopathic or hereditary dystonia in Finland at 405 per million,^[@R7]^ whereas a meta-analysis estimated the prevalence of isolated dystonia at 164 per 1,000,000^8^. However, genetic forms such as DYT1 represent a minority of those cases. The prevalence of the GAG deletion in *TOR1A* among patients of all ages presenting with idiopathic dystonia has been addressed following a forward genetics approach, with reported rates of 5% (France),^[@R17]^ 3.4% (Japan),^[@R18]^ 2.3% (Germany),^[@R19]^ 1.5% (Taiwan),^[@R20]^ or 7% (Poland).^[@R21]^ If, based on these reports, we consider these dystonia prevalence data (405 per million) and the approximate frequency of the GAG deletion among those patients (5%), there would be approximately 6,252 patients with DYT1 in the United States. Another approach to evaluate DYT1 prevalence is to use epidemiologic data including only early-onset idiopathic dystonia, the most common phenotypical presentation of DYT1. The prevalence of early-onset idiopathic dystonia in the United States has been reported at 1 in 30,000,^[@R22]^ with about 70% of those predicted to carry the DYT1 mutation.^[@R23]^ Using these rates, the estimate would amount to 7,204 DYT1 patients in the United States. Both clinical ascertainment-based estimates are significantly lower than the range of 16,475 to 24,513 DYT1 patients yielded by this genetic ascertainment approach.

There are different potential reasons for this discrepancy. First, penetrance could be lower than the estimated 30%. The families used for penetrance studies were recruited through clinical ascertainment of affected family members followed by genetic screening of unaffected relatives. However, it is possible that many families carry the GAG deletion with no expression of dystonia. A second reason for the discrepancy between clinical and genetic ascertainment approaches is underdiagnosis (or misdiagnosis) of DYT1 of dystonia.

Finally, our data do not support an association of the D216H polymorphism with isolated dystonia. However, these data should be taken with caution because of the pitfalls of using diagnostic codes from EHR for genotype-phenotype correlations, especially in a challenging and heterogeneous syndrome such as dystonia.

In this work, we report the frequency of the most common DYT1 mutation in the general population using large genetic data sets, with additional data on rare pathogenic and a clinically significant polymorphism. Together with clinically ascertained information, we provide a solid prevalence estimate for DYT1. This information establishes the size of the target population for genetically driven precision therapies for DYT1.
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